Literature DB >> 20358424

HE4: a new potential early biomarker for the recurrence of ovarian cancer.

Emanuela Anastasi1, Giulia Giovanna Marchei, Valentina Viggiani, Giuseppina Gennarini, Luigi Frati, Maria Gabriella Reale.   

Abstract

Human epididymis protein 4 (HE4) has recently been described as a new marker for the early diagnosis of ovarian cancer (OC). The objective of this study was to evaluate (a) the expression of HE4 vs. OC mucin CA125 in 32 patients with OC compared to 163 patients with other malignant or benign pathologies (b) HE4 as indicator of the recurrence of the disease in eight patients followed-up for 20 months after OC diagnosis. Serum HE4 and CA 125 levels were determined by ELISA and IRMA, respectively. At diagnosis, the patients with OC demonstrated high levels of both biomarkers with 96.9% sensitivity for HE4 and 85.7% for CA125. In the other pathologies there was 3.7% positivity for HE4 and 21.0% for CA125. The follow-up study showed an increase of HE4 5-8 months before CA125 increment in five of the eight patients, this early expression being strictly associated to a relapse of the disease. In conclusion, this study showed that HE4, compared to CA125, potentially is a better marker for the diagnosis of OC and could be an important early indicator of the recurrence of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20358424     DOI: 10.1007/s13277-009-0015-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  Comprehensive analysis of HE4 expression in normal and malignant human tissues.

Authors:  Mary T Galgano; Garret M Hampton; Henry F Frierson
Journal:  Mod Pathol       Date:  2006-06       Impact factor: 7.842

2.  Estimates of the worldwide incidence of 25 major cancers in 1990.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  Int J Cancer       Date:  1999-03-15       Impact factor: 7.396

Review 3.  Current initial therapy of stage III and IV ovarian cancer: challenges for managed care.

Authors:  J C Schink
Journal:  Semin Oncol       Date:  1999-02       Impact factor: 4.929

4.  Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Authors:  Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

Review 5.  Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review.

Authors:  Lidia Rosi Medeiros; Daniela Dornelles Rosa; Maria Inês da Rosa; Mary Clarisse Bozzetti
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2008-11-07       Impact factor: 2.435

Review 6.  Role of genetic polymorphisms and ovarian cancer susceptibility.

Authors:  Peter A Fasching; Simon Gayther; Leigh Pearce; Joellen M Schildkraut; Ellen Goode; Falk Thiel; Georgia Chenevix-Trench; Jenny Chang-Claude; Shan Wang-Gohrke; Susan Ramus; Paul Pharoah; Andrew Berchuck
Journal:  Mol Oncol       Date:  2009-02-04       Impact factor: 6.603

7.  Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.

Authors:  D X Chen; P E Schwartz; X G Li; Z Yang
Journal:  Obstet Gynecol       Date:  1988-07       Impact factor: 7.661

Review 8.  SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.

Authors:  Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 9.  Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis.

Authors:  Mark Harries; Martin Gore
Journal:  Lancet Oncol       Date:  2002-09       Impact factor: 41.316

Review 10.  CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Authors:  Chunqiao Tian; Maurie Markman; Richard Zaino; Robert F Ozols; William P McGuire; Franco M Muggia; Peter G Rose; David Spriggs; Deborah K Armstrong
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

View more
  47 in total

1.  Preclinical evaluation of Mab CC188 for ovarian cancer imaging.

Authors:  M Xu; M P Rettig; G Sudlow; B Wang; W J Akers; D Cao; D G Mutch; J F DiPersio; S Achilefu
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

2.  Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

Authors:  Teresa Granato; Cecilia Midulla; Flavia Longo; Barbara Colaprisca; Luigi Frati; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-04-13

3.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Authors:  Richard G Moore; Michael Craig Miller; Elizabeth E Eklund; Karen H Lu; Robert C Bast; Geralyn Lambert-Messerlian
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

4.  Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.

Authors:  Yan Zhang; Chunxia Qiao; Lian Li; Xuye Zhao; Yali Li
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

5.  Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma.

Authors:  Keita Tokuishi; Shin-ichi Yamashita; Kazuyuki Ohbo; Katsunobu Kawahara
Journal:  Tumour Biol       Date:  2011-10-21

6.  Does HE4 have a role as biomarker in the recurrence of ovarian cancer?

Authors:  Francesco Plotti; Stella Capriglione; Corrado Terranova; Roberto Montera; Alessia Aloisi; Patrizio Damiani; Ludovico Muzii; Giuseppe Scaletta; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Tumour Biol       Date:  2012-08-09

Review 7.  Seminal plasma as a diagnostic fluid for male reproductive system disorders.

Authors:  Andrei P Drabovich; Punit Saraon; Keith Jarvi; Eleftherios P Diamandis
Journal:  Nat Rev Urol       Date:  2014-04-08       Impact factor: 14.432

Review 8.  Role of biomarkers for early detection of ovarian cancer recurrence.

Authors:  Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco
Journal:  Gland Surg       Date:  2020-08

9.  Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.

Authors:  Ying Shen; Li Li
Journal:  Tumour Biol       Date:  2016-09-15

10.  Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

Authors:  Nicole Urban; Jason Thorpe; Beth Y Karlan; Martin W McIntosh; Melanie R Palomares; Mary B Daly; Pamela Paley; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-09-07       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.